- CA$42.43m
- CA$70.88m
- CA$17.75m
- 19
- 60
- 22
- 24
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.67 | ||
| Price to Tang. Book | 3.89 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.58 | ||
| EV to EBITDA | 8.99 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 12.07% | ||
| Return on Equity | 12.13% | ||
| Operating Margin | 21% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | n/a | n/a | n/a | 10.03 | 17.75 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
LSL Pharma Group Inc. is a Canadian integrated pharmaceutical company specializing in the development, manufacturing and commercialization of sterile ophthalmic pharmaceutical products, as well as pharmaceutical, cosmetic and natural health products in solid, semi-solid and liquid dosage forms. The Company’s segments include CMO activities and Integrated Eye-care pharmaceutical company. Its contract manufacturing operations include LSL Laboratory, Inc., Dermolab Pharma Ltd., Virage Sante Inc., and Laboratoire Du-Var Inc. LSL Laboratory, Inc. is engaged in the manufacturing of natural health products in solid dosage forms. Dermolab Pharma Ltd. manufactures liquid and semi-solid pharmaceutical, natural health and cosmetic products. Steri-Med Pharma Inc., the Company’s sterile eye-care manufacturing operation, specializes in the in-licensing or development/manufacturing and commercialization of sterile ophthalmic pharmaceuticals for Canada, United States and other international markets.
Directors
- Marcel Tremblay CHM
- Alain Larochelle CEO
- Claude Gauthier CFO
- Pierre-Hubert Seguin SEC
- Stephane Beshro IND
- Roger Boucher IND
- Paul Forest IND
- Last Annual
- December 31st, 2024
- Last Interim
- September 30th, 2025
- Incorporated
- July 12th, 2010
- Public Since
- March 8th, 2011
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
TSX Venture Exchange- Shares in Issue
- 121,220,176
- Address
- 540, rue d'Avaugour, Office 1800, BOUCHERVILLE, J4B 0G6
- Web
- https://www.groupelslpharma.com/
- Phone
- +1 4506817744
- Auditors
- Audacie Inc
Upcoming Events for LSL
Similar to LSL
Aequus Pharmaceuticals
TSX Venture Exchange
Arch Biopartners
TSX Venture Exchange
Biosyent
TSX Venture Exchange
Cytophage Technologies
TSX Venture Exchange
Decibel Cannabis
TSX Venture Exchange
FAQ
As of Today at 20:49 UTC, shares in LSL Pharma are trading at CA$0.35. This share price information is delayed by 15 minutes.
Shares in LSL Pharma last closed at CA$0.35 and the price had moved by over the past 365 days. In terms of relative price strength the LSL Pharma share price has underperformed the Toronto Stock Exchange 300 Composite Index by -22.65% over the past year.
There is no consensus recommendation for this security.
Find out moreLSL Pharma does not currently pay a dividend.
LSL Pharma does not currently pay a dividend.
LSL Pharma does not currently pay a dividend.
To buy shares in LSL Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$0.35, shares in LSL Pharma had a market capitalisation of CA$42.43m.
Here are the trading details for LSL Pharma:
- Country of listing: Canada
- Exchange: CVE
- Ticker Symbol: LSL
Based on an overall assessment of its quality, value and momentum LSL Pharma is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like LSL Pharma. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -26.7%.
As of the last closing price of CA$0.35, shares in LSL Pharma were trading -6.01% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The LSL Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.35.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
LSL Pharma's management team is headed by:
- Marcel Tremblay - CHM
- Alain Larochelle - CEO
- Claude Gauthier - CFO
- Pierre-Hubert Seguin - SEC
- Stephane Beshro - IND
- Roger Boucher - IND
- Paul Forest - IND